igforum.bio / programa-de-terapia-de-celulas-t-con-receptores-de-antigeno-quimerico-ensayos-clinicos-mayo-clinic - 151916
S
%Begin Programa de terapia de células T con receptores de antígeno quimérico - Ensayos clínicos - Mayo Clinic <h2>COVID-19 consejos información actualizada y opciones de vacunas</h2> Infórmate sobre la COVID-19 y las vacunas contra esta enfermedad, y conoce las novedades para pacientes y visitantes de Mayo Clinic. Para navegación del sitio Para acceso a contenido Este contenido no tiene una versión en inglésEste contenido no tiene una versión en árabe Search Pida una consulta Para encontrar un doctor Para encontrar trabajo Para donar Acceso a su cuenta de paciente Español English العربية 简体中文 Twitter Facebook Pinterest YouTube Menú Solicite una Consulta Departamentos y centros Centros y departamentos médicos <h1>Programa de terapia de células T con receptores de antígeno quimérico</h1> <h2>Ensayos clínicos</h2> Solicite una Consulta en Mayo Clinic Preguntas frecuentesRemisiones Feb.
Sofia Garcia Member
access_time 3 minutes ago
%Begin Programa de terapia de células T con receptores de antígeno quimérico - Ensayos clínicos - Mayo Clinic

COVID-19 consejos información actualizada y opciones de vacunas

Infórmate sobre la COVID-19 y las vacunas contra esta enfermedad, y conoce las novedades para pacientes y visitantes de Mayo Clinic. Para navegación del sitio Para acceso a contenido Este contenido no tiene una versión en inglésEste contenido no tiene una versión en árabe Search Pida una consulta Para encontrar un doctor Para encontrar trabajo Para donar Acceso a su cuenta de paciente Español English العربية 简体中文 Twitter Facebook Pinterest YouTube Menú Solicite una Consulta Departamentos y centros Centros y departamentos médicos

Programa de terapia de células T con receptores de antígeno quimérico

Ensayos clínicos

Solicite una Consulta en Mayo Clinic Preguntas frecuentesRemisiones Feb.
thumb_up Like (26)
comment Reply (1)
share Share
visibility 749 views
thumb_up 26 likes
comment 1 replies
D
Daniel Kumar 3 minutes ago
19, 2022 Comparte en: FacebookTwitter A continuación, se enumeran los ensayos clínicos actuales.
V
19, 2022 Comparte en: FacebookTwitter A continuación, se enumeran los ensayos clínicos actuales.<br>18 estudios en Programa de terapia de células T con receptores de antígeno quimérico<br> (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. <h3>A Study to Evaluate Remote Monitoring in Cancer Care</h3> Rochester, Minn.
Victoria Lopez Member
access_time 2 minutes ago
19, 2022 Comparte en: FacebookTwitter A continuación, se enumeran los ensayos clínicos actuales.
18 estudios en Programa de terapia de células T con receptores de antígeno quimérico
(solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc.

A Study to Evaluate Remote Monitoring in Cancer Care

Rochester, Minn.
thumb_up Like (33)
comment Reply (3)
thumb_up 33 likes
comment 3 replies
A
Aria Nguyen 1 minutes ago
The objectives of this study are to establish the validity for the use of wearable device for cont...
S
Sophia Chen 1 minutes ago

A Study to Assess CART19 for B Cell Malignancies

Rochester, Minn. The purpose of this study...
Show 1 more replies
N
The objectives of this study are to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, and to develop patient-specific algorithms to predict the trajectory of CRS and or neurotoxicity and time to escalation of medical intervention is needed. <h3>Exploring the Role of B-cell Activating Factor Receptor BAFFR -based Chimeric Antigen Receptor T-cell CAR T in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders</h3> Jacksonville, Fla. The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.
Nathan Chen Member
access_time 3 minutes ago
The objectives of this study are to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, and to develop patient-specific algorithms to predict the trajectory of CRS and or neurotoxicity and time to escalation of medical intervention is needed.

Exploring the Role of B-cell Activating Factor Receptor BAFFR -based Chimeric Antigen Receptor T-cell CAR T in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders

Jacksonville, Fla. The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models.
thumb_up Like (15)
comment Reply (0)
thumb_up 15 likes
V
<h3>A Study to Assess CART19 for B Cell Malignancies</h3> Rochester, Minn. The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe for patients. The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer.
Victoria Lopez Member
access_time 4 minutes ago

A Study to Assess CART19 for B Cell Malignancies

Rochester, Minn. The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe for patients. The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer.
thumb_up Like (50)
comment Reply (1)
thumb_up 50 likes
comment 1 replies
E
Evelyn Zhang 4 minutes ago
T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the ...
A
T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the patient's T cells will be removed from their blood.
Audrey Mueller Member
access_time 15 minutes ago
T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the patient's T cells will be removed from their blood.
thumb_up Like (44)
comment Reply (0)
thumb_up 44 likes
D
In the laboratory, we will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat the cancer.
Daniel Kumar Member
access_time 18 minutes ago
In the laboratory, we will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat the cancer.
thumb_up Like (49)
comment Reply (0)
thumb_up 49 likes
K
The new modified T cells are called the IC19/1563 treatment. The dose of IC19/1563 will depend on when the patient is enrolled on to the study. <h3>A Study to Evaluate CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies</h3> Jacksonville, Fla.
Kevin Wang Member
access_time 7 minutes ago
The new modified T cells are called the IC19/1563 treatment. The dose of IC19/1563 will depend on when the patient is enrolled on to the study.

A Study to Evaluate CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies

Jacksonville, Fla.
thumb_up Like (28)
comment Reply (3)
thumb_up 28 likes
comment 3 replies
V
Victoria Lopez 4 minutes ago
The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relap...
M
Mason Rodriguez 5 minutes ago

A Study to Provide Access to CTL019 Out of Specification Managed Access Program MAP for ALL or...

Show 1 more replies
O
The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relapsed or refractory B cell malignancies. <h3>A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma</h3> Scottsdale/Phoenix, Ariz. The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD).
Oliver Taylor Member
access_time 8 minutes ago
The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relapsed or refractory B cell malignancies.

A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma

Scottsdale/Phoenix, Ariz. The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD).
thumb_up Like (20)
comment Reply (3)
thumb_up 20 likes
comment 3 replies
C
Charlotte Lee 3 minutes ago

A Study to Provide Access to CTL019 Out of Specification Managed Access Program MAP for ALL or...

L
Liam Wilson 2 minutes ago
The purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in pa...
Show 1 more replies
D
<h3>A Study to Provide Access to CTL019 Out of Specification Managed Access Program MAP for ALL or DLBCL Patients</h3> Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. <h3>Open-label Multi-center Phase 1b 2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T-cells CT053 in Patients</h3> Rochester, Minn., Scottsdale/Phoenix, Ariz.
Dylan Patel Member
access_time 18 minutes ago

A Study to Provide Access to CTL019 Out of Specification Managed Access Program MAP for ALL or DLBCL Patients

Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.

Open-label Multi-center Phase 1b 2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T-cells CT053 in Patients

Rochester, Minn., Scottsdale/Phoenix, Ariz.
thumb_up Like (42)
comment Reply (2)
thumb_up 42 likes
comment 2 replies
C
Charlotte Lee 16 minutes ago
The purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in pa...
A
Andrew Wilson 10 minutes ago
The purpose of this research study is to find out if the experimental treatment, ALLO-715 in combina...
E
The purpose of this study is to evaluate&nbsp;Chimeric Antigen Receptor T Cells targeting BCMA in patients with myeloma. <h3>Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma UNIVERSAL </h3> Rochester, Minn.
Emma Wilson Admin
access_time 40 minutes ago
The purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in patients with myeloma.

Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma UNIVERSAL

Rochester, Minn.
thumb_up Like (30)
comment Reply (3)
thumb_up 30 likes
comment 3 replies
D
Dylan Patel 19 minutes ago
The purpose of this research study is to find out if the experimental treatment, ALLO-715 in combina...
N
Nathan Chen 30 minutes ago

A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Mye...

Show 1 more replies
C
The purpose of this research study is to find out if the experimental treatment, ALLO-715 in combination with ALLO-647, is safe and effective in treating multiple myeloma. <h3>A Study to Evaluate ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid Round Cell Liposarcoma</h3> Jacksonville, Fla. The purpose of this study is to evaluate genetically-engineered ADP-A2M4 in HLA-A*02 subjects with metastatic or inoperable (advanced) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) who have received prior chemotherapy and whose tumor expresses the MAGE-A4 tumor antigen.
Chloe Santos Moderator
access_time 11 minutes ago
The purpose of this research study is to find out if the experimental treatment, ALLO-715 in combination with ALLO-647, is safe and effective in treating multiple myeloma.

A Study to Evaluate ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid Round Cell Liposarcoma

Jacksonville, Fla. The purpose of this study is to evaluate genetically-engineered ADP-A2M4 in HLA-A*02 subjects with metastatic or inoperable (advanced) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) who have received prior chemotherapy and whose tumor expresses the MAGE-A4 tumor antigen.
thumb_up Like (48)
comment Reply (3)
thumb_up 48 likes
comment 3 replies
A
Alexander Wang 10 minutes ago

A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Mye...

A
Amelia Singh 4 minutes ago
Programa de terapia de células T con receptores de antígeno quimérico - Ensayos clínicos - Mayo ...
Show 1 more replies
R
<h3>A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Myeloma</h3> Jacksonville, Fla., Rochester, Minn. The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information. <h2>Programa de terapia de células T con receptores de antígeno quimérico</h2>Página inicial del departamentoSeccionesDescripción generalInformación sobre el tratamiento de células T con receptores de antígenos quiméricosNuestro programaMédicosPreguntas frecuentesEnsayos clínicosRemisiones <h3>Investigación todo es por los pacientes</h3> <h2>Secciones</h2>Solicite una ConsultaDescripción generalInformación sobre el tratamiento de células T con receptores de antígenos quiméricosNuestro programaMédicosPreguntas frecuentesEnsayos clínicosRemisiones ORG-20404311 Departamentos y centros Centros y departamentos médicos Programa de terapia de células T con receptores de antígeno quimérico
Ryan Garcia Member
access_time 24 minutes ago

A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Myeloma

Jacksonville, Fla., Rochester, Minn. The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per the approved prescribing information.

Programa de terapia de células T con receptores de antígeno quimérico

Página inicial del departamentoSeccionesDescripción generalInformación sobre el tratamiento de células T con receptores de antígenos quiméricosNuestro programaMédicosPreguntas frecuentesEnsayos clínicosRemisiones

Investigación todo es por los pacientes

Secciones

Solicite una ConsultaDescripción generalInformación sobre el tratamiento de células T con receptores de antígenos quiméricosNuestro programaMédicosPreguntas frecuentesEnsayos clínicosRemisiones ORG-20404311 Departamentos y centros Centros y departamentos médicos Programa de terapia de células T con receptores de antígeno quimérico
thumb_up Like (2)
comment Reply (1)
thumb_up 2 likes
comment 1 replies
V
Victoria Lopez 4 minutes ago
Programa de terapia de células T con receptores de antígeno quimérico - Ensayos clínicos - Mayo ...

Write a Reply

Similar Discussions